FrancophonIA/ELRC3.0 huggingface dataset:
English: Obeticholic acid has minimal renal elimination with less than 3% of the dose recovered in urine.
Maltese: Obeticholic acid għandu eliminazzjoni minima mill-kliewi b'inqas minn 3% tad-doża rikoverata mill-awrina.
English: For patients in the OCALIVA titration arm whose OCALIVA dosage was increased from 5 mg once daily to 10 mg once daily, additional reductions in ALP were observed at Month 12 in the majority of patients.
Maltese: Għal pazjenti fil-parti tal-istudju b'titrazzjoni ta' OCALIVA liema dożaġġ b'OCALIVA ġie miżjud minn 5 mg darba kuljum għal 10 mg darba kuljum, tnaqqis addizzjonali ta' ALP ġie osservat f'Xahar 12 fil-maġġoranza tal-pazjenti.
English: • rash
Maltese: Sess
English: - OCALIVA 10 mg is a yellow, triangular film-coated tablet with ‘INT' on one side and ‘10' on the other side of the film-coated tablet.
Maltese: - OCALIVA 10 mg hija pillola safra, trijangulari u miksija b'rita, b'‘INT' fuq naħa waħda u ‘10'
English: Therapeutic monitoring of CYP1A2 substrates with narrow therapeutic index (e.g. theophylline and tizanidine) is recommended.
Maltese: Monitoraġġ terapewtiku ta' substrati ta' CYP1A2 b'indiċi terapewtiku dejjaq (eż. theophylline u tizanidine) huwa rakkomandat.
English: Patients were randomised (1:1:1) to receive once daily placebo, OCALIVA 10 mg, or OCALIVA titration (5 mg titrated to 10 mg at 6 months dependent on therapeutic response/tolerability).
Maltese: Pazjenti ġew magħżula b'mod każwali(1:1:1) sabiex darba kuljum jirċievu plaċebo, OCALIVA 10 mg, jew titrazzjoni ta' OCALIVA
English: NAME OF THE MEDICINAL PRODUCT OCALIVA 5 mg film-coated tablets obeticholic acid
Maltese: OCALIVA 5 mg pilloli miksija b'rita obeticholic acid
English: OCALIVA 5 mg film-coated tablets: Each film-coated tablet contains 5 mg of obeticholic acid.
Maltese: U KWANTITATTIVA OCALIVA 5 mg pilloli miksija b'rita Kull pillola miksija b'rita fiha 5 mg obeticholic acid.
English: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Maltese: - Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe sustanza mhux attiva elenkata fis-sezzjoni 6.1. - Ostruzzjoni biljari kompluta
English: The mean age was 56 years, with the majority of patients less than 65 years old.
Maltese: Letà medja kienet ta' 56 sena, bil-maġġoranza tal- pazjenti inqas minn 65 sena.
English: The impact of mild hepatic impairment (Child-Pugh Class A) on the pharmacokinetics of obeticholic acid was negligible, therefore, no dose adjustment is necessary for patients with mild hepatic impairment.
Maltese: L-impatt ta' indeboliment ħafif tal-fwied (Child-Pugh Klassi A) fuq il-farmakokinetika ta' obeticholic acid kien negliġibbli, għaldaqstant, l-ebda aġġustament tad-doża ma huwa meħtieġ għal pazjenti b'indeboliment ħafif tal-fwied.
English: Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.
Maltese: Obethicolic acid huwa konġugat ma' glycine jew tuarine fil-fwied u mneħħi fil-bilja.
English: Based on animal studies and intended pharmacology, obeticholic acid is not expected to interfere with breast-feeding or the growth or development of a breast-fed child. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from obeticholic acid therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman (see section 5.3).
Maltese: Skont studju fuq lannimali u l-farmakoloġija intiża, obeticholic acid mhux mistenni jinterferixxi mat-treddigħ jew mattikbir jew l-iżvilupp tal-wild li qed jiġi mreddgħa.
English: • Reducing the dosage of obeticholic acid to: ▪ 5 mg once weekly, for patients intolerant to 5 mg twice weekly ▪ 10 mg once weekly, for patients intolerant to 10 mg twice weekly
Maltese: ▪ 5 mg darba fil-ġimgħa, għal pazjenti li ma jittollerawx 5 mg darbtejn fil-ġimgħa ▪ 10 mg darba kuljum, għal pazjenti li ma jittollerawx 10 mg darbtejn fil-ġimgħa
English: NAME OF THE MEDICINAL PRODUCT OCALIVA 10 mg film-coated tablets obeticholic acid
Maltese: OCALIVA 10 mg pilloli miksija b'rita obeticholic acid
English: • stomach pain
Maltese: Qalba tal-pillola
English: If you take bile acid binding resins, take this medicine at least 4-6 hours before or at least 4-6 hours after the bile acid binding resin (see section "Other medicines and OCALIVA").
Maltese: Jekk tieħu kwalunkwe minn dawn il-mediċini, ħu OCALIVA tal-anqas 4-6 sigħat qabel jew 4-6 sigħat wara li tieħu r-reżina li tintrabat mal-aċidu talbili, biex tħalli l-itwal intervall ta' ħin possibbli.
English: There is little information about the effects of OCALIVA in pregnancy.
Maltese: Hemm informazzjoni limitata dwar l-effetti ta' OCALIVA fit-tqala.
English: Further information on Intelence can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It contains the active substance etravirine.
Maltese: Fih is-sustanza attiva etravirine.
English: Other information about Intelence
Maltese: Informazzjoni oħra dwar Intelence
English: Intelence is available as tablets (25, 100 and 200 mg) to be swallowed whole with a glass of water.
Maltese: Intelence jiġi bħala pilloli (25, 100 u 200 mg) li għandhom jinbelgħu sħaħ ma' tazza ilma.
English: The active substance in Intelence, etravirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Maltese: Is-sustanza attiva f'Intelence, l-etravirine, hija inibitur mhux nukleosidiku tat-transkrittażi inversa (NNRTI).
English: This overview was last updated in 07-2018.
Maltese: Din il-ħarsa ġenerali ġiet aġġornata l-aħħar f'07-2018.
English: HIV-1 is a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: HIV-1 huwa virus li jikkawża s-sindrome ta' immunodefiċjenza akkwiżita (AIDS).
English: Intelence received a marketing authorisation valid throughout the EU on 28 August 2008.
Maltese: Intelence rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-28 ta' Awwissu 2008.
English: Intelence is a medicine for treating human immunodeficiency virus type 1 (HIV-1) in adults and children from 6 years of age.
Maltese: Intelence huwa mediċina għall-kura tal-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1) fl-adulti u fit-tfal minn età ta' 6 snin.
English: In two main studies in a total of 1,203 adults, the average viral load was 70,000 copies/ml at the start of treatment.
Maltese: F'żewġ studji ewlenin f'total ta' 1,203 adulti, it-tagħbija virali medja kienet ta' 70,000 kopja/ml fil-bidu tal-kura.
English: In adults, the recommended dose of Intelence is 200 mg twice a day after a meal while in children the dose depends on body weight and ranges from 100 mg twice a day to 200 mg twice a day.
Maltese: Fl-adulti, id-doża rakkomandata ta' Intelence hija ta' 200 mg darbtejn kuljum wara l-ikel filwaqt li fittfal, id-doża tiddependi mill-piż tal-ġisem u tvarja minn 100 mg darbtejn kuljum għal 200 mg darbtejn kuljum.
English: What are the risks associated with Intelence?
Maltese: X'inhuma r-riskji assoċjati ma' Intelence?
English: Intelence must not be used together with elbasvir/grazoprevir, a medicine to treat hepatitis C infection.
Maltese: Intelence m'għandux jintuża flimkien ma' elbasvir/grazoprevir, mediċina għall-kura tal-infezzjoni talepatite C.
English: As for all medicines, data on the use of Intelence are continuously monitored.
Maltese: Bħal għall-mediċini kollha, id-data dwar l-użu ta' Intelence hija ssorveljata kontinwament.
English: After 24 weeks, 59% of the patients taking Intelence together with other HIV medicines had undetectable levels of HIV, compared with 41% of those taking placebo (a dummy treatment) plus the other HIV medicines.
Maltese: Wara 24 ġimgħa, 59 % tal-pazjenti li kienu qed jieħdu Intelence flimkien ma' mediċini oħrajn tal-HIV kellhom livelli mhux traċċabbli tal-HIV, meta mqabbel ma' 41 % ta' dawk li kienu qed jieħdu plaċebo (kura finta) flimkien mal-mediċini l-oħra tal-HIV.
English: In a main study of 101 children aged between 6 and 17 years, about half of them had undetectable levels of HIV after 24 weeks of taking Intelence in combination with other medicines, and the proportion of children with undetectable levels of HIV increased slightly after 48 weeks.
Maltese: Fi studju ewlieni ta' 101 tifel/tifla ta' età bejn 6 u 17-il sena, madwar nofshom kellhom livelli ta' HIV mhux traċċabbli wara 24 ġimgħa minn meta ħadu Intelence flimkien ma' mediċini oħrajn, u lproporzjon ta' tfal b'livelli mhux traċċabbli ta' HIV żdied ftit wara 48 ġimgħa.
English: Studies have shown that Intelence, in combination with other medicines, is effective at reducing the level of HIV in the blood (viral load) to undetectable levels (below 50 copies/ml) in many patients with HIV-1 infection.
Maltese: L-istudji wrew li Intelence, meħud flimkien ma' mediċini oħra, huwa effettiv biex inaqqas il-livell talHIV fid-demm (tagħbija virali) għal livelli mhux traċċabbli (inqas minn 50 kopja/ml) f'ħafna pazjenti b'infezzjoni tal-HIV-1.
English: The most common side effects with Intelence (which may affect more than 1 in 10 people) are rash, diarrhoea, nausea (feeling sick) and headache.
Maltese: L-effetti sekondarji l-aktar komuni b'Intelence (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma raxx, dijarea, nawsja (tħossok ma tiflaħx) u uġigħ ta' ras.
English: For the full list of side effects and restrictions with Intelence, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Intelence, ara l-fuljett ta' tagħrif.
English: Intelence does not cure HIV infection or AIDS, but it may delay damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Intelence ma jikkurax infezzjoni tal-HIV jew l-AIDS, iżda jista' jittardja l-ħsara lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: What benefits of Intelence have been shown in studies?
Maltese: X'inhuma l-benefiċċji ta' Intelence li ħarġu mill-istudji?
English: Intelence is effective at reducing viral load to undetectable levels in both adults and children and its side effects are considered manageable.
Maltese: Intelence huwa effettiv biex inaqqas it-tagħbija virali għal livelli mhux traċċabbli kemm fl-adulti kif ukoll fit-tfal u l-effetti sekondarji tiegħu jitqiesu ġestibbli.
English: Side effects reported with Intelence are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Intelence huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: By blocking this enzyme, Intelence, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Maltese: Billi jimblokka din l-enzima, Intelence, meta jittieħed flimkien ma' mediċini oħra tal-HIV, inaqqas l-ammont ta' HIV fid-demm u jżommu f'livell baxx.
English: How is Intelence used?
Maltese: Kif jintuża Intelence?
English: It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells in the body and make more viruses.
Maltese: Din timblokka l-attività tat-transkrittażi inversa, enzima prodotta mill-HIV li tħalliha tinfetta ċ-ċelloli fil-ġisem u tipproduċi aktar virusijiet.
English: 10 June 2010
Maltese: 10 Ġunju 2010
English: 1 Article 35 of Directive 2001/82/EC
Maltese: 1 L-Artikolu 35 tad-Direttiva 2001/82/KE
English: The rapporteur and co-rapporteur appointed were: Prof. Christian Friis and Dr Karolina Törneke, respectively.
Maltese: Ir-rapporteur u l-ko-rapporteur maħtura kienu: ilProfessur Christian Friis u t-Tabiba Karolina Törneke, rispettivament.
English: Colistin sulfate is a polypeptide antibiotic belonging to the polymyxins group of antibiotics.
Maltese: Colistin sulfate huwa antibijotiku polipeptidu (polypeptide antibiotic) li jappartjeni għall-grupp ta' antibijotiċi polymyxins.
English: Opinion following an Article 35
Maltese: Opinjoni wara referenza skont l-Artikolu 35
English: The referral procedure started on 16 April 2009.
Maltese: Il-proċedura ta' referenza bdiet fis-16 ta' April 2009.
English: Written explanations were provided by the applicants/marketing authorisation holders on 15 July 2009 and 13 January 2010.
Maltese: Spjegazzjonijiet bil-miktub kienu pprovduti mill-applikanti/detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq fil-15 ta' Lulju 2009 u fit-13 ta' Jannar 2010.
English: Veterinary medicinal formulations containing colistin sulfate at 2 000 000 IU per ml and intended for administration via drinking water to calves, pigs, lambs and poultry are used for the treatment of infections of the gastrointestinal tract caused by Escherichia coli and Salmonella spp susceptible to colistin.
Maltese: Il-formulazzjonijiet mediċinali veterinarji li fihom colistin sulfate bi 2 000 000 IU għal kull ml u maħsubin sabiex jingħataw permezz tal-ilma tax-xorb lill-għoġġiela, lillħnieżer, lill-ħrief u lit-tjur jintużaw għat-trattament ta' infezzjonijiet tal-passaġġ gastrointestinali kkawżati minn Escherichia coli u Salmonella spp suxxettibbli għal colistin.
English: Due to concerns that the differences in posology and withdrawal periods established across the European Union for veterinary medicinal formulations containing colistin at 2 000 000 IU per ml and intended for administration in drinking water to food producing species may present a potential serious risk to public and animal health, the United Kingdom referred the matter to the Agency on 1 April 2009, under Article 35 of Directive 2001/82/EC.
Maltese: Minħabba tħassib li d-differenzi fil-pożoloġija u l-perjodi ta' rtirar stabbiliti madwar l-Unjoni Ewropea għall-formulazzjonijiet mediċinali veterinarji li fihom colistin bi 2 000 000 IU għal kull ml u maħsubin sabiex jingħataw permezz tal-ilma tax-xorb lill-ispeċi li jipproduċu l-ikel jistgħu jippreżentaw riskju potenzjali serju għas-saħħa pubblika u dik tal-annimali, ir-Renju Unit irrefera l-kwistjoni lill-Aġenzija fl-1 ta' April 2009, skont l-Artikolu 35 tad-Direttiva 2001/82/KE.
English: referral for veterinary medicinal formulations containing colistin at 2 000 000 IU per ml and intended for administration in drinking water to food producing species
Maltese: għal formulazzjonijiet mediċinali veterinarji li fihom colistin bi 2 000 000 IU f'kull ml u maħsubin sabiex jingħataw flilma tax-xorb lil speċi li jipproduċu l-ikel
English: Based on the rapporteurs' assessment of the currently available data, the CVMP, adopted, on 10 February 2010, an opinion recommending variations of the marketing authorisations for veterinary medicinal formulations containing colistin at 2 000 000 IU per ml and intended for administration in drinking water to food producing species in order to amend the summary of the product characteristics (SPC), labelling and package leaflet to harmonise the posology and withdrawal periods (where applicable) for the concerned products.
Maltese: IU għal kull ml u maħsuba għallamministrazzjoni fl-ilma tax-xorb lill-ispeċi li jipproduċu l-ikel sabiex jiġu emendata s-sommarju talkaratteristiċi tal-prodott (SPC) , it-tikketta u l-fuljett ta' tagħrif għall-armonizzar tal-pożoloġija u lperjodi ta' rtirar (fejn japplikaw) għall-prodotti kkonċernati.
English: EMA/686158/2014 EMEA/H/C/000610
Maltese: EMEA/H/C/000610
English: The full EPAR for Noxafil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Noxafil posaconazole
Maltese: Noxafil posakonażol
English: This summary was last updated in 09-2014.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'09-2014.
English: • simvastatin, lovastatin or atorvastatin (used to lower cholesterol).
Maltese: • simvastatin, lovastatin jew atorvastatin (użati għat-tnaqqis tal-kolesterol).
English: This document is a summary of the European public assessment report (EPAR) for Noxafil.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Noxafil.
English: Noxafil is an antifungal medicine that contains the active substance posaconazole; it is available as an oral suspension (40 mg/ml), a concentrate (300 mg) for solution for infusion (drip) into a vein and as gastroresistant tablets (100 mg).
Maltese: Noxafil huwa mediċina antifungali li fiha s-sustanza attiva posakonażol; jiġi bħala sospensjoni orali (40 mg/ml). konċentrat (300 mg) għal soluzzjoni għal infużjoni (dripp) fil-vina u bħala pilloli gastroreżistenti (100 mg).
English: • terfenadine, astemizole (used for allergy),
Maltese: • terfenadina, astemiżol (użati għall-allerġija),
English: Other information about Noxafil
Maltese: Informazzjoni oħra dwar Noxafil
English: • fusariosis (fungal infection caused by Fusarium),
Maltese: • fusarjożi (infezzjoni fungali kkawżata b'Fusarium),
English: The active substance in Noxafil, posaconazole, is an antifungal medicine that belongs to the triazole group.
Maltese: Is-sustanza attiva f'Noxafil, il-posakonażol, hija mediċina antifungali li tappartjeni għall-grupp tattriażol.
English: • invasive aspergillosis (fungal infection caused by Aspergillus),
Maltese: • asperiġillożi invażiva (infezzjoni fungali kkawżata b'Aspergillus),
English: Why has Noxafil been approved?
Maltese: Għaliex ġie approvat Noxafil?
English: In oropharyngeal candidiasis, Noxafil oral suspension was as effective as fluconazole.
Maltese: F'kandidjażi orofaringeali, is-sospensjoni orali Noxafil kienet effettiva daqs flukonażol.
English: • ergotamine or dihydroergotamine (used to treat migraine),
Maltese: • ergotamina jew diidroergotamina (użati għall-kura tal-emigranja),
English: Other common side effects include vomiting, diarrhoea, pyrexia (fever) and increased bilirubin (a sign of liver problems) in the blood.
Maltese: Effetti sekondarji komuni oħrajn jinkludu remettar, dijarea, piressija (deni) u żieda fil-livell ta' bilirubina (sinjal ta' problemi fil-fwied) fid-demm.
English: In the prevention studies, Noxafil oral suspension was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Noxafil group, and 9% in the comparator group.
Maltese: Fl-istudji ta' prevenzjoni, is-sospensjoni orali Noxafil kienet effettiva daqs flukonażol f'pazjenti bi trapjant ta' ċelloli staminali, b'5% tal-pazjenti li żviluppaw infezzjoni fil-grupp ta' Noxafil, u 9% filgrupp komparatur.
English: The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Noxafil group, and 8% in the comparator groups.
Maltese: Il-mediċina kienet aktar effettiva minn flukonażol jew itrakonażol f'pazjenti bilkanċer, bi 2% tal-pazjenti li żviluppaw infezzjoni fil-grupp ta' Noxafil, u 8% fil-gruppi komparaturi.
English: The study included 107 patients with aspergillosis, 18 patients with fusariosis, 11 with chromoblastomycosis or mycetoma, and 16 with coccidioidomycosis.
Maltese: L-istudju kien jinkludi 107 pazjenti b'asperġillożi, 18-il pazjent b'fusarjożi, 11 bi kromoblastomikożi jew miċetoma, u 16 b'koċċidioidomikożi.
English: • halofantrine (used to treat malaria),
Maltese: • alofantrina (użata għall-kura tal-malarja),
English: In one main study, Noxafil oral suspension was studied in 238 patients with invasive fungal infections that did not respond to standard antifungal treatment.
Maltese: Fi studju wieħed prinċipali, is-sospensjoni orali Noxafil ġiet studjata f'238 pazjent b'infezzjonijiet fungali invażivi li ma rrispondewx għal-kura antifungali standard.
English: Noxafil also successfully treated 11 of the 18 patients who had proven or probable fusariosis, 9 of the 11 patients with chromoblastomycosis or mycetoma, and 11 of the 16 patients with coccidioidomycosis.
Maltese: Noxafil ikkura wkoll b'suċċess lil 11 mit-18-il pazjent li kellhom fusarjożi ppruvata jew probabbli, 9 mill-11-il pazjent bi kromoblastomikożi jew miċetoma, u 11 mis-16-il pazjent b'koċċidioidomikożi.
English: Noxafil oral suspension and tablets have different dosages and should not be used interchangeably.
Maltese: Is-sospensjoni orali u l-pilloli Noxafil għandhom dożaġġi differenti u ma jistgħux jintużaw b'mod alternat.
English: Noxafil is used to treat adults (aged 18 years or over) with the following fungal diseases, when treatments with other antifungal medicines (amphotericin B, itraconazole or fluconazole) cannot be tolerated or have failed:
Maltese: Noxafil jintuża għall-kura ta' adulti (minn 18-il sena 'l fuq) bil-mard fungali li ġej, meta kuri b'mediċini antifungali oħrajn (amfoteriċina B, itrakonażol jew flukonażol) ma jistgħux jiġu ttollerati jew ma kellhomx suċċess:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Noxafil on 25 October 2005.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Noxafil valida fl-Unjoni Ewropea kollha fil-25 ta' Ottubru 2005.
English: For the prevention of invasive fungal infections, Noxafil oral suspension is given at a dose of 200 mg (5 ml) three times a day.
Maltese: Għall-prevenzjoni ta' infezzjonijiet fungali invażivi, is-sospensjoni orali Noxafil tingħata f'doża ta' 200 mg (5 ml) tliet darbiet kuljum.
English: • quinidine (used for irregular heart beat),
Maltese: • kwinidina (quinidine) (użata għat-taħbit irregolari tal-qalb),
English: The list of fungi against which Noxafil is active can be found in the summary of product characteristics (also part of the EPAR).
Maltese: Il-lista ta' fungi li Noxafil huwa attiv kontrihom hija disponibbli fis-sommarju tal-karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: For oral candidiasis, Noxafil oral suspension is taken as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
Maltese: Għal kandidjażi orali, is-sospensjoni orali Noxafil tittieħed bħala 200 mg (5 ml) flewwel jum segwita minn 100 mg (2.5 ml) darba kuljum għal 13-il jum wara.
English: In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Noxafil oral suspension, compared with 26% of the patients in the comparator group.
Maltese: F'asperġillożi invażiva, deher rispons b'suċċess fit-tmiem tal-kura fi 42% tal-pazjenti li ħadu ssospensjoni orali Noxafil, meta mqabbel ma' 26% tal-pazjenti fil-grupp komparatur.
English: • pimozide (used for treating mental illness),
Maltese: • pimozide (użata għall-kura ta' mard mentali),
English: What is Noxafil?
Maltese: Għal xiex jintuża Noxafil?
English: • chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters),
Maltese: • kromoblastomikożi u miċetoma (infezzjonijiet fungali tal-ġilda jew tat-tessut eżatt taħt il-ġilda għall-perjodu fit-tul, normalment ikkawżati minn spori fungali li jinfettaw il-ġrieħi minħabba xewk jew skaldi),
English: In another main study involving 350 HIV-infected patients with oropharyngeal candidiasis, Noxafil oral suspension was compared with fluconazole.
Maltese: Fi studju prinċipali ieħor li kien jinvolvi 350 pazjent infettati bl-HIV b'kandidjażi orofaringeali, is-sospensjoni orali Noxafil tqabblet ma' flukonażol.
English: Noxafil oral suspension, solution for infusion and gastro-resistant tablets are also used to prevent invasive fungal infections in patients whose immune system is weakened because of treatments they are receiving for blood or bone marrow cancers or medicines used in haematopoietic stem cell transplantation (a transplant of cells that make blood cells).
Maltese: Is-sospensjoni orali, is-soluzzjoni għal infużjoni u l-pilloli gastroreżistenti Noxafil jintużaw ukoll għallprevenzjoni ta' infezzjonijiet fungali invażivi f'pazjenti li s-sistema immunitarja tagħhom iddgħajfet minħabba l-kuri li qegħdin jirċievu għall-kanċer fid-demm jew fil-mudullun jew mediċini użati fittrapjant ta' ċelloli staminali ematopojetiċi (trapjant ta' ċelloli li jagħmlu ċ-ċelloli tad-demm).
English: What is the risk associated with Noxafil?
Maltese: X'inhu r-riskju assoċjat ma' Noxafil?